3/26
09:12 am
atos
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth [Yahoo! Finance]
Medium
Report
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth [Yahoo! Finance]
3/26
08:19 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
3/25
08:18 am
atos
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/25
08:00 am
atos
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Medium
Report
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
3/20
09:13 am
atos
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
3/12
08:05 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
3/11
08:15 am
atos
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
Medium
Report
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
2/5
08:00 am
atos
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
Low
Report
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
1/30
12:45 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
1/30
08:17 am
atos
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
Medium
Report
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
1/23
08:15 am
atos
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
Low
Report
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
1/6
09:00 am
atos
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
Medium
Report
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer